---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-304559"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2025-12-02T23:59:59+00:00"
generated_at: "2026-05-16T15:40:05.756591+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology completes first U.S. commercial sale of KOMZIFTI, triggering $135M milestone payment from Kyowa Kirin

## Summary
- First commercial sale of KOMZIFTI (ziftomenib) completed on December 2, 2025.
- Milestone triggers $135M payment from Kyowa Kirin, expected before year-end 2025.
- KOMZIFTI received FDA approval on November 13, 2025.
- Payment is under the existing collaboration and license agreement with Kyowa Kirin.

## SEC filing metadata
- accession: 0001193125-25-304559
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2025-12-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000119312525304559/0001193125-25-304559-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000119312525304559/d75668d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-304559
- JSON: https://secwatch.observer/filing/0001193125-25-304559.json
- Plain text: https://secwatch.observer/filing/0001193125-25-304559.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.